Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods

Diagnostic Microbiology and Infectious Disease

Volumn 33, Issue 4, 1999, Pages 247-253

  Jones, Ronald N ^a   Kugler, Kari C ^a   Erwin, Meredith E ^a   Biedenbach, Douglas J ^a   Beach, Mondell L ^a   Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN;

AEROBIC BACTERIUM; AGAR GEL DIFFUSION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; INTERMETHOD COMPARISON; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; TECHNIQUE;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; LEAST-SQUARES ANALYSIS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; QUALITY CONTROL;

EID: 0033056144     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00086-8     Document Type: Article

References (21)

1. Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM-1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J Antimicrob Chemother. 40:1997;639-651.
2. Deguchi T., Yasuda M., Nakano M., Ozeki S., Kanematsu E., Fukuda H., Maeda S., Saito I., Kawada Y. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alternations in gyr A and par C. Chemotherapy. 43:1997;239-244.
3. Gavan T.L., Jones R.N., Barry A.L., Fuchs P.C., Gerlach E.H., Matsen J.M., Reller L.B., Thornsberry C., Thrupp L.D. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests A collaborative study . J Clin Microbiol. 14:1981;67-72.
4. Hosaka M., Kinoshita S., Toyama A., Otsuki M., Nishino T. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother. 36:1995;293-301.
5. Hosaka M., Yasue T., Fukuda H., Tomizawa H., Aoyama H., Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 36:1992;2108-2117.
6. Ishida K., Kaku M., Irifune K., Mizukane R., Takemura H., Yoshida R., Tanaka H., Usui T., Tomono K., Suyama N. In vitro and in vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae. J Antimicrob Chemother. 34:1994;875-883.
7. Kato N., Kato H., Tanaka-Bandoh K., Watanabe K., Ueno K. Comparative in vitro and in vivo activity of AM-1155 against anaerobic bacteria. J Antimicrob Chemother. 40:1997;631-637.
8. Miyashita N., Niki Y., Kishimoto T., Nakajima M., Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother. 41:1997;1331-1334.
9. Muraki Y., Yamada M., Nii S., Kumon H., Ohmori H. In vitro assessment of relative phototoxicity of quinolone antibacterial agents by reduction of neutral red uptake in cultured cells. Jpn J Chemother. 43:1995;357-360.
10. Nakashima M., Uematsu T., Kosuge K., Kusajima H., Dori T., Masuda Y., Ishida R., Uchida H. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 39:1995;2635-2640.
11. National Committee for Clinical Laboratory Standards (NCCLS) . Performance Standards for Antimicrobial Disk Susceptibility Tests, 6th Ed. Approved Standard M2-A6. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
12. National Committee for Clinical Laboratory Standards (NCCLS) . Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th Ed. Approved Standard M7-A4. 1997;NCCLS, Wayne, PA.
13. National Committee for Clinical Laboratory Standards (NCCLS) . Performance Standards for Antimicrobial Susceptibility Testing. Supplemental Table M100-S8. 1998;NCCLS, Wayne, PA.
14. National Committee for Clinical Laboratory Standards (NCCLS) . Development of in Vitro Susceptibility Testing Criteria and Quality Control Parameters. Tentative Guideline M23-T3. 1998;NCCLS, Wayne, PA.
15. Soejima R., Miyashita N., Nakabayashi M., Kimura M., Hashiguchi K., Kishimoto T. In vitro activities of AM-1155 against Chlamydia spp. and M. avium complex. Drugs. 45:(Suppl. 3):1993;181.
16. Tanaka M., Matsumoto T., Kobayshi I., Uchino U., Kumazawa J. Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolates in Japan. Antimicrob Agents Chemother. 39:1995;2367-2370.
17. Tomioka H., Saito H., Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother. 37:1993;1259-1263.
18. Tomizawa H., Tateda K., Miyazaki S., Yamaguchi K. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 41:1998;103-106.
19. Wakabayashi E., Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 38:1994;594-601.
20. Wise R., Brenwald N.P., Andres J.M., Boswell F. The activity of the methylpiperazinyl fluoroquinolone CG 5501 A comparison with other fluoroquinolones . J Antimicrob Chemother. 39:1997;447-452.
21. Yamamoto T., Kusajima H., Hosaka M., Fukuda H., Oomori Y., Shinoda H. Uptake and intracellular activity of AM-1155 in phagocytic cells. Antimicrob Agents Chemother. 40:1996;2756-2759.